Infectex initiates enrollment in SQ109 Phase IIb-III trial for MDR-TB
The trial will compare the effects of an optimized background drug regimen alone with an optimized background regimen plus SQ109 in MDR-TB patients.
Source: Sequella
The trial will compare the effects of an optimized background drug regimen alone with an optimized background regimen plus SQ109 in MDR-TB patients.
Source: Sequella
